{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:11:18Z","timestamp":1780481478171,"version":"3.54.1"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T00:00:00Z","timestamp":1481241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["99.165"],"award-info":[{"award-number":["99.165"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006020","name":"Center for Translational Molecular Medicine","doi-asserted-by":"publisher","award":["01 C-201"],"award-info":[{"award-number":["01 C-201"]}],"id":[{"id":"10.13039\/501100006020","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["2011 T12"],"award-info":[{"award-number":["2011 T12"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0164485","type":"journal-article","created":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T14:10:02Z","timestamp":1481292602000},"page":"e0164485","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":22,"title":["Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists"],"prefix":"10.1371","volume":"11","author":[{"given":"Nienke","family":"van Rein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem M.","family":"Lijfering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mettine H. A.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martien H.","family":"Herruer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga W.","family":"Vermaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix J. M.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter H.","family":"Reitsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,12,9]]},"reference":[{"issue":"6 Suppl","key":"ref1","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"J Ansell","year":"2008","journal-title":"Chest"},{"issue":"13","key":"ref2","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/archinte.1993.00410130073007","article-title":"Bleeding complications in oral anticoagulant therapy. An analysis of risk factors","volume":"153","author":"FJ van der Meer","year":"1993","journal-title":"Arch Intern Med"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.blre.2013.02.004","article-title":"Bleeding risks associated with vitamin K antagonists","volume":"27","author":"LA Linkins","year":"2013","journal-title":"Blood Rev"},{"issue":"6 Suppl","key":"ref4","doi-asserted-by":"crossref","first-page":"257S","DOI":"10.1378\/chest.08-0674","article-title":"Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"S Schulman","year":"2008","journal-title":"Chest"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0002-9343(98)00198-3","article-title":"Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin","volume":"105","author":"RJ Beyth","year":"1998","journal-title":"Am J Med"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study","volume":"58","author":"MC Fang","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"BF Gage","year":"2006","journal-title":"Am Heart J"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/archinte.159.5.457","article-title":"Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism","volume":"159","author":"PM Kuijer","year":"1999","journal-title":"Arch Intern Med"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"GY Lip","year":"2010","journal-title":"Chest"},{"issue":"10","key":"ref10","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1161\/01.STR.0000141933.75462.c2","article-title":"Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients","volume":"35","author":"TI Shireman","year":"2004","journal-title":"Stroke"},{"issue":"9","key":"ref11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/clc.22435","article-title":"The HAS-BLED Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis","volume":"38","author":"W Zhu","year":"2015","journal-title":"Clin Cardiol"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","article-title":"A simple salting out procedure for extracting DNA from human nucleated cells","volume":"16","author":"SA Miller","year":"1988","journal-title":"Nucleic Acids Res"},{"key":"ref13","unstructured":"Trombosediensten FvN. FNT- NORMEN. 2015 2015. Report No."},{"issue":"13","key":"ref14","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1001\/archinternmed.2009.170","article-title":"Thrombomodulin as a marker for bleeding complications during warfarin treatment","volume":"169","author":"M Lind","year":"2009","journal-title":"Arch Intern Med"},{"issue":"25","key":"ref15","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.jacc.2010.12.033","article-title":"Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients","volume":"57","author":"V Roldan","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"ref16","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1538-7836.2004.00768.x","article-title":"Non-fatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX","volume":"2","author":"JF van der Heijden","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jclinepi.2013.05.011","article-title":"Suspected survivor bias in case-control studies: stratify on survival time and use a negative control","volume":"67","author":"N van Rein","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"9025","key":"ref18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(96)01109-9","article-title":"Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy","volume":"348","author":"G Palareti","year":"1996","journal-title":"Lancet"},{"issue":"20","key":"ref19","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1001\/jama.290.20.2685","article-title":"Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?","volume":"290","author":"AS Go","year":"2003","journal-title":"JAMA"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"FR Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"e000067","DOI":"10.1161\/JAHA.112.000067","article-title":"Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial","volume":"2","author":"DE Singer","year":"2013","journal-title":"J Am Heart Assoc"},{"issue":"20","key":"ref22","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/CIRCULATIONAHA.107.750000","article-title":"Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range","volume":"118","author":"SJ Connolly","year":"2008","journal-title":"Circulation"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archinte.167.3.239","article-title":"Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V","volume":"167","author":"HD White","year":"2007","journal-title":"Arch Intern Med"},{"issue":"10","key":"ref24","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7326\/0003-4819-141-10-200411160-00005","article-title":"Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation","volume":"141","author":"MC Fang","year":"2004","journal-title":"Ann Intern Med"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(89)80689-8","article-title":"Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy","volume":"87","author":"CS Landefeld","year":"1989","journal-title":"Am J Med"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJM199507063330103","article-title":"Optimal oral anticoagulant therapy in patients with mechanical heart valves","volume":"333","author":"SC Cannegieter","year":"1995","journal-title":"N Engl J Med"},{"issue":"7","key":"ref27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.7326\/0003-4819-118-7-199304010-00005","article-title":"Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group","volume":"118","author":"SD Fihn","year":"1993","journal-title":"Ann Intern Med"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0002-9343(86)90260-3","article-title":"Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhage","volume":"81","author":"DB Petitti","year":"1986","journal-title":"Am J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0164485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T07:11:37Z","timestamp":1568617897000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0164485"}},"subtitle":[],"editor":[{"given":"Valder R.","family":"Arruda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,12,9]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0164485","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,9]]}}}